Study Title
AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP)
Protocol ID
AAML18P1
Condition/s
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Diagnosis Stage
On treatment
Location
VIC, WA
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Sites
Monash Children's Hospital
Perth Children's Hospital
The Royal Children's Hospital
Perth Children's Hospital
The Royal Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
up to 25 years
International registry ID's
NCT03817398
| Study Title | AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia – Chronic Phase (CML-CP) |
|---|---|
| Protocol ID | AAML18P1 |
| Disease (Sub Disease) | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive |
| Diagnosis Stage | On treatment |
| Location | VIC / WA |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT03817398 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 15/07/2019 |
| Sites | Monash Children's Hospital / Perth Children's Hospital / The Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | up to 25 years |
| International registry ID's | NCT03817398 |